Skip to content

The CAN-RELEASE study: Canadian real-life effectiveness of eptinezumab in migraine patients

Migraine | Headache

This study aims to evaluate effectiveness in adult migraine patients who have initiated eptinezumab according to the local prescribing information, as well as the treatment patterns and health care resource utilisation (HCRU) in clinical practice.

null

Conditions de participation

  • Sexe:

    Male, Female, Intersex

  • Âges admissibles:

    18 and up

Critères de participation

Inclusion Criteria:
• The patient has either Episodic Migraine (with 4 or more episodes per month), or Chronic Migraine.
• The patient is at least age 18.
• The patient is initiating eptinezumab according to the local prescribing information as part of routine care but has not yet received their first infusion.
• The patient is willing to bring their own device and download and use the provided application software.
Exclusion Criteria:
• The patient has been administered investigational drugs within at least 3 months of enrollment.
• A time gap ˃ 2 months exists between patient informed consent and the date of first infusion, unless the patient has reconsented.
• The patient has previously been enrolled and dosed in any study with eptinezumab.

Lieu de l'étude

University of Calgary
University of Calgary
Calgary, Alberta
Canada

Contactez l'équipe d'étude

Étude parrainée par
University of Calgary
Participants recherchés
Plus d'informations
ID de l'étude: REB24-0483